Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.56 |
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.51 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.51 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.49 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023 | 0.98 | HPGD (0.60) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL31418947 | 0.98 | HPGD (0.60) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Ammonia Solution, Strong SCHEMBL27428848 | 0.96 | HPGD (0.58) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Bicarbonate SCHEMBL8424367 | 0.91 | MAOB (0.62) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Pyrene SCHEMBL28909258 | 0.89 | HSD17B3 (0.56) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Acetic Acid SCHEMBL1698232 | 0.89 | MAOB (0.63) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Phosphonic Acid SCHEMBL28608612 | 0.89 | HPGD (0.56) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Diethylamine SCHEMBL9359210 | 0.86 | MAOB (0.55) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL23573103 | 0.84 | MAOA (0.47) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Methacrylic Acid SCHEMBL31073510 | 0.84 | MAOB (0.56) | HPGDSMN1; SMN2TYRDAOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20210220276-A1 | Methods of Treating Skin | LABORATORY SKIN CARE, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20200138718-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10350168-B2 | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | LABORATORY SKIN CARE, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170340566-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9707177-B2 | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | LABORATORY SKIN CARE, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150004232-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20130309276-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445002-B2 | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | LABORATORY SKIN CARE, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110189239-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2011-08-04 | — | — | US | disclosed |
| EP-1485365-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485354-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| US-6365359-B1 | IDENTIFYING PRP PHARMACORE BY DETERMINING FUNCTIONAL RESIDUES OF PROTEIN INVOLVED IN COMPLEX INTERACTIONS, DEVELOPING THREE DIMENSIONAL STRUCTURES, COMPARING THEM WITH OTHER COMPOUNDS AND IDENTIFYING COMPOUNDS CONSISTENT WITH BINDING TO PROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-02 | — | — | US | disclosed |
| CN-1130381-A | Use of coumarins and carbostyrils as PLAZ inhibitors, new coumarins and carbostyrils, process for prep, the same and medicaments | BOEHERINGER MANNHEIM GMBH (DE) | 1996-09-04 | — | — | CN | disclosed |
| CN-1107151-A | Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders | SANKYO CO (JP) | 1995-08-23 | — | — | CN | disclosed |
| CN-1028527-C | Process for preparing coumarin derivatives | SANKYO CO (JP) | 1995-05-24 | — | — | CN | disclosed |
| CN-1049662-A | Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder | SANKYO CO (JP) | 1991-03-06 | — | — | CN | disclosed |